GSK plc announced on January 13, 2025, that it will acquire IDRx, Inc. for up to $1.15 billion to enhance its gastrointestinal cancer portfolio, including a promising therapy, IDRX-42, for treating gastrointestinal stromal tumors (GIST) which targets key mutations and has shown a 29% response rate in trials.